Overview

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

Study will deteremine the MTD and evaluate the safety profile of oral lenalidomide on days 1-14 when combined with pemetrexed on day 1 of a 21 days cycle. Subjects will continue on study until documention of disease progression.

Phase:

Phase 1

Details

Lead Sponsor:

Celgene Corporation

Collaborator:

Prologue Research International

Treatments:

Lenalidomide
Pemetrexed
Thalidomide